SAN FRANCISCO — In a year's experience with the NuvaRing contraceptive, 2.3% of women experience an expulsion, according to the results of four large, phase III clinical trials, Marc Kaptein, M.D., and Edio Zampaglione, M.D., said in a poster presentation at the annual meeting of the American College of Obstetricians and Gynecologists.
In a retrospective analysis of 3,333 women and 33,462 cycles, expulsion occurred in 0.5% of cycles, said the researchers from Organon International, which makes NuvaRing.
The proportion of cycles with expulsions decreased with time, likely due to experience. In the first three cycles, 1.7% reported an expulsion. Users were followed for 13 cycles. In the 11th, 12th, and 13th cycles, 0.2% experienced expulsions.